Targeting Neuroinflammation in Alzheimer's Disease: Repurposed Nucleoside Reverse Transcriptase Inhibitors and the Therapeutic Potential of Kamuvudine-9 - PubMed
3 hours ago
- #Neuroinflammation
- #Alzheimer's Disease
- #Drug Repurposing
- NRTIs, originally antiretrovirals, show potential for modifying Alzheimer's disease by targeting neuroinflammation.
- They inhibit the NLRP3 inflammasome, reduce amyloid and tau pathology, and modulate neuroinflammation.
- Kamuvudine-9 is a second-generation NRTI designed with reduced toxicity for safer long-term use in neurodegenerative diseases.
- NRTIs and Kamuvudine-9 act on inflammatory and genetic mechanisms affecting both amyloid and tau pathology.
- Future prospects include precision medicine and nanocarrier delivery for accessible, disease-modifying AD treatments.